Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iAnthus Capital HoldingsFRA:2IA Debt-to-EBITDA is 22.03 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, iAnthus Capital Holdings ranks worse than 98.12% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for iAnthus Capital Holdings's Debt-to-EBITDA or its related term are showing as below:
FRA:2IA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -77.51 Med: -0.55 Max: 47.06
Current: 47.06
During the past 11 years, the highest Debt-to-EBITDA Ratio of iAnthus Capital Holdings was 47.06. The lowest was -77.51. And the median was -0.55.
FRA:2IA's Debt-to-EBITDA is ranked worse than 98.12% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs FRA:2IA: 47.06
iAnthus Capital Holdings (FRA:2IA) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
iAnthus Capital Holdings Debt-to-EBITDA Related Terms
iAnthus Capital Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, iAnthus Capital Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iAnthus Capital Holdings Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iAnthus Capital Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where iAnthus Capital Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
iAnthus Capital Holdings (FRA:2IA) has a Debt-to-EBITDA of 22.03 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on iAnthus Capital Holdings. According to the industry distribution chart, iAnthus Capital Holdings ranks #677 out of 690 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is iAnthus Capital Holdings' Debt-to-EBITDA too high?
iAnthus Capital Holdings' current Debt-to-EBITDA is 22.03. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. iAnthus Capital Holdings' value of 22.03 is 1235.2% above this industry median. Based on the distribution chart, iAnthus Capital Holdings ranks #677 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does iAnthus Capital Holdings' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, iAnthus Capital Holdings ranks #677 out of 690 companies for Debt-to-EBITDA. This places iAnthus Capital Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. iAnthus Capital Holdings' value of 22.03 is 1235.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iAnthus Capital Holdings's current Debt-to-EBITDA of 22.03 is 1235.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on iAnthus Capital Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iAnthus Capital Holdings's current Debt-to-EBITDA is 22.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iAnthus Capital Holdings stock overvalued right now?
iAnthus Capital Holdings (FRA:2IA) has a current Debt-to-EBITDA of 22.03. The current Debt-to-EBITDA is 22.03 and 1235.2% above the Drug Manufacturers industry median of 1.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For iAnthus Capital Holdings (FRA:2IA), the current Debt-to-EBITDA is 22.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iAnthus Capital Holdings Inc is a vertically-integrated, multi-state owner and operator of licensed cannabis cultivation, processing, and dispensary facilities and a developer, producer, and distributor of branded cannabis products in the United States. Its Cannabis product offerings include flower and trim, products containing cannabis flower and trim (such as packaged flower and pre-rolls), cannabis infused products (such as topical creams and edibles), and products containing cannabis extracts (such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures). The company's reportable operating segments are the Eastern Region, which generates the maximum revenue, and the Western Region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2IA has been successfully added to your 
